Refractory Rheumatoid Arthritis

Refractory Rheumatoid Arthritis - The reRA Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005807

Enrollment

219

Registered

2014-02-28

Start date

2014-12-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M05

Interventions

Group 1: Refraktory rheumatoid arthritis: - Treatment failures - Moderate/high disease activity - radiological progression We will perform clinical, functional, imaging (ultrasound), and biochemical

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Rheumatoide arthritis: Cases (refractory RA): high/ moderate disease activity despite >4 DMARDs; Controls: achievement of remission/low disease activity within th first two DMARD courses.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
This is not a therapeutical study with primary/secondary endpoints. Refractory patients will be matched with non.refractory patients. Numerous clinical, biochemical, structural, functional, serological, and gentic markers will be investigated. The final number of markers will be adapted to the final number of cases and controls (using principal component analysis). Thus, the main analysis (multiple regression of relevant markers) will have sufficent power to identify the independent effects of the most relevant markers.	—

Measure

Time frame

This is not a therapeutical study with primary/secondary endpoints. Refractory patients will be matched with non.refractory patients. Numerous clinical, biochemical, structural, functional, serological, and gentic markers will be investigated. The final number of markers will be adapted to the final number of cases and controls (using principal component analysis). Thus, the main analysis (multiple regression of relevant markers) will have sufficent power to identify the independent effects of the most relevant markers.

—

Secondary

Measure	Time frame
No specific secondary endpoints (see above)	—

Countries

Austria

Contacts

Public ContactDaniel Aletaha

Abteilung für RheumatologieMedizinische Universität Wien

daniel.aletaha@meduniwien.ac.at+431404006209

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026